|
|
|
Harnack House, Berlin, Germany
09 - 12 September 2018
Following the sold-out second edition in 2016, you can expect more superb science, networking opportunities and discussion on the latest topics. We are pleased to announce that Professor Hans Clevers will give the opening keynote lecture, and Professor Donald Ingber will give the closing keynote lecture. The programme will feature a session dedicated to immunotherapy for the first time, with Professor Ronald Germain giving the immunotherapy keynote lecture. Who should attend? The target audience for this conference is basic and translational scientists and clinicians, both senior and young investigators that want to have a broad and detailed overview of the most recent advances in the study of tumour biology, bioengineering and biochemistry, drug target validation, compound and antibody screening, toxicology, and patient-tumour profiling.
|
|
|
|
|
|
Organized by:
|
|
European Association for Cancer Research |
|
Invited Speakers:
|
|
Hans Clevers (Netherlands), Janine Erler (Denmark), Andrew Ewald (USA), Claudia Fischbach-Teschl (USA), Reinhold Förster (Germany), Margaret Frame (UK), Peter Friedl (Netherlands/USA), Ronald Germain (USA), Donald Ingber (USA), Fanny Jaulin (France), Matthias Lütolf (Switzerland), Ellen Van Obberghen-Schilling (France), Emmy Verschuren (Finland), Danijela Vignjevic (France), Maria Vinci (Italy), Bettina Weigelin (Netherlands/USA)
|
|
|
|
|
|
Deadline for Abstracts:
|
|
15 June 2018
|
|
|
|
|
|
Registration:
|
|
Deadline: 31 July 2018
|
|
E-mail:
|
|
roger.doxat-pratt@nottingham.ac.uk
|
|
|
|
|
|
|
|